Ozempic and Wegovy Linked to Rare Sudden Vision Loss Risk

What the New Study Reveals

Researchers at Rutgers University have identified a modest rise in the incidence of a rare eye disorder among patients taking the GLP‑1 medications Ozempic (semaglutide) and Wegovy (semaglutide for weight loss). The condition, known as ischemic optic neuropathy (ION), can lead to abrupt and sometimes permanent loss of vision. While the absolute risk remains very low, the findings have drawn attention because of the growing popularity of these drugs for diabetes management and obesity treatment.

The study examined health records of more than 1.5 million individuals who were prescribed GLP‑1 agonists between 2018 and 2023. Researchers found that the rate of ION in this group was approximately 0.03 cases per 10,000 person‑years, compared with 0.01 cases in a matched control group not using GLP‑1 therapy. This translates to a three‑fold relative increase, though the overall likelihood of any single patient developing the condition stays well below one in ten thousand.

For context, the researchers noted that ION is already a rare cause of vision loss, accounting for less than 5 percent of all optic neuropathies in the United States. The study was published in the journal Ophthalmology and has been highlighted in a press release by Rutgers Rutgers University News.

Understanding the Rare Vision Condition

Ischemic optic neuropathy occurs when the blood supply to the optic nerve is compromised. The optic nerve transmits visual information from the retina to the brain, so any interruption can cause sudden visual field defects, blurred vision, or complete loss of sight in the affected eye.

Two main forms of ION exist:

• Anterior ION – affects the front portion of the optic nerve and often presents with painless vision loss.
• Posterior ION – involves the back portion of the nerve and may be associated with subtle visual changes that progress rapidly.

Risk factors traditionally include severe hypertension, diabetes, atherosclerosis, and certain inflammatory disorders. The new data suggest that GLP‑1 therapy could be an additional, albeit minor, contributor.

How GLP‑1 Drugs Work

Both Ozempic and Wegovy belong to a class of medications called glucagon‑like peptide‑1 (GLP‑1) receptor agonists. They mimic a natural hormone that stimulates insulin release, slows gastric emptying, and reduces appetite. These actions help lower blood glucose levels in type 2 diabetes and promote weight loss in obesity.

Because GLP‑1 receptors are also present in blood vessels, some scientists hypothesize that prolonged activation may affect microvascular circulation, including the tiny vessels that feed the optic nerve. However, the exact biological mechanism linking GLP‑1 drugs to ION remains under investigation.

Who Is Most at Risk

While the study did not pinpoint a single high‑risk profile, certain characteristics appeared more common among the affected individuals:

1. Age over 60 years.
2. History of cardiovascular disease or uncontrolled hypertension.
3. Concurrent use of medications that influence blood pressure, such as certain antihypertensives.
4. Long‑term exposure to GLP‑1 therapy (more than 12 months).

Patients without these factors still experienced ION, reinforcing that the association is probabilistic rather than deterministic.

Symptoms and When to Seek Care

Early recognition of ION can improve outcomes. Common warning signs include:

• Painless loss of vision in one eye.
• Sudden decrease in visual sharpness.
• Difficulty distinguishing colors, especially reds and greens.
• Seeing a dark spot or shadow in the peripheral vision.

If any of these symptoms appear, prompt evaluation by an eye specialist is essential. The American Academy of Ophthalmology recommends immediate referral to an ophthalmologist for a comprehensive retinal and optic nerve assessment Ischemic Optic Neuropathy Overview.

Medical Community Response

The FDA has acknowledged the study and reminded clinicians to remain vigilant for ocular side effects when prescribing GLP‑1 agonists. A recent safety communication can be found on the agency’s website FDA Drug Safety Updates. The agency has not issued new labeling changes but encourages reporting of any adverse eye events through the MedWatch system.

Professional societies such as the Endocrine Society have issued statements urging endocrinologists to discuss the potential, though rare, eye risks with patients during shared decision‑making. They also recommend coordination with primary care providers and ophthalmologists for patients who have pre‑existing vascular risk factors.

Guidance for Patients Using Ozempic or Wegovy

Current guidance emphasizes balance between the proven benefits of GLP‑1 drugs—improved glycemic control, weight reduction, and cardiovascular risk lowering—and the newly identified eye risk. Patients are advised to:

• Maintain regular blood pressure checks and manage hypertension aggressively.
• Schedule an annual eye exam, especially if they have diabetes or a history of vascular disease.
• Report any sudden visual changes to a healthcare professional without delay.
• Discuss alternative diabetes or weight‑loss therapies if they have a strong personal or family history of optic nerve disorders.

Importantly, clinicians stress that discontinuing Ozempic or Wegovy without medical advice could jeopardize glycemic control and increase cardiovascular risk.

Future Research Directions

Rutgers investigators plan to conduct prospective studies that monitor ocular blood flow in patients beginning GLP‑1 therapy. They also aim to explore whether dose adjustments or intermittent dosing schedules might mitigate the risk.

Other research groups, including the National Eye Institute, are reviewing large health‑system databases to confirm the association and identify any genetic predispositions. The outcome of these studies will inform whether formal label updates become necessary.

In the meantime, the medical community continues to weigh the low absolute risk of ION against the substantial benefits of GLP‑1 drugs for millions of people living with diabetes and obesity.